Results 21 to 30 of about 4,767 (196)

Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity [PDF]

Molecular Therapy: Oncolytics, 2016
In oncolytic virotherapy, the ability of the virus to activate the immune system is a key attribute with regard to long-term antitumor effects. Vaccinia viruses bear one of the strongest oncolytic activities among all oncolytic viruses.
Mari Hirvinen, Cristian Capasso, Kilian Guse, Mariangela Garofalo, Andrea Vitale, Marko Ahonen, Lukasz Kuryk, Markus Vähä-Koskela, Akseli Hemminki, Vittorio Fortino, Dario Greco, Vincenzo Cerullo   +11 more
doaj   +2 more sources

3D bioprinted CRC model brings to light the replication necessity of an oncolytic vaccinia virus encoding FCU1 gene to exert an efficient anti-tumoral activity [PDF]

Frontiers in Oncology
The oncolytic virus represents a promising therapeutic strategy involving the targeted replication of viruses to eliminate cancer cells, while preserving healthy ones. Despite ongoing clinical trials, this approach encounters significant challenges. This
Christophe A. Marquette, Emma Petiot, Anita Spindler, Caroline Ebel, Mael Nzepa, Baptiste Moreau, Philippe Erbs, Jean-Marc Balloul, Eric Quemeneur, Cécile Zaupa   +9 more
doaj   +2 more sources

Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68

BMC Cancer, 2011
Background Oncolytic viral therapy represents an alternative therapeutic strategy for the treatment of cancer. We previously described GLV-1h68, a modified Vaccinia Virus with exclusive tropism for tumor cells, and we observed a cell line-specific ...
Bedognetti Davide, Di Pasquale Giovanni, Roychoudhuri Rahul, Pos Zoltan, Chen Nanhai G, Adams Sharon, Reinboth Jennifer, Yu Zhiya, Worschech Andrea, Ascierto Maria, Uccellini Lorenzo, Rossano Fabio, Ascierto Paolo A, Stroncek David F, Restifo Nicholas P, Wang Ena, Szalay Aladar A, Marincola Francesco M   +17 more
doaj   +2 more sources

Theranostic Potential of Oncolytic Vaccinia Virus [PDF]

Theranostics, 2012
Biological cancer therapies, such as oncolytic, or replication-selective viruses have advantages over traditional therapeutics as they can employ multiple different mechanisms to target and destroy cancers (including direct cell lysis, immune activation and vascular collapse). This has led to their rapid recent clinical development.
Rojas, Juan J, Thorne, Steve H
openaire   +4 more sources

Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma

Frontiers in Immunology, 2023
BackgroundThe attenuated, genetically engineered vaccinia virus has been shown to be a promising oncolytic virus for the treatment of patients with solid tumors, through both direct cytotoxic and immune-activating effects.
Navin K. Chintala, Jennie K. Choe, Erin McGee, Rebecca Bellis, Jasmeen K. Saini, Srijita Banerjee, Andre L. Moreira, Marjorie G. Zauderer, Prasad S. Adusumilli, Prasad S. Adusumilli, Valerie W. Rusch   +10 more
doaj   +1 more source

Vinorelbine enhances the efficacy of oncolytic vaccinia virus in a preclinical model of ovarian high-grade serous carcinoma. [PDF]

Mol Ther Oncol
Vaccinia virus, known for its clinical safety, has a tropism for primary and metastatic tumors as well as ovarian tissue. Consequently, oncolytic approaches with recombinant vaccinia viruses have emerged as attractive agents against ovarian cancer ...
Drymiotou S, Queval CJ, Tyson KE, Sheach LA, Postigo A, Rosa ID, Ennis DP, Howell M, McNeish IA, Way M.   +9 more
europepmc   +2 more sources

Global trends of Vaccinia oncolytic virus therapy over the past two decades: Bibliometric and visual analysis

Frontiers in Immunology, 2023
BackgroundIn recent years, the vaccinia oncolytic virus has entered the clinical trial stage of examination and shown good progress. It has many advantages, such as good safety, high oncolytic efficiency, and the regulation ability of the tumor ...
Liu Bo, Liu Tianming, Fan Fengliang, Liang Wenping, Han Jinzuo, Xue Dongbo, Ma Biao, Sun Haijun   +7 more
doaj   +1 more source

Giving Oncolytic Vaccinia Virus More BiTE [PDF]

Molecular Therapy, 2014
Two of the most exciting new areas of cancer therapy are the use of oncolytic viruses and immune-stimulating monoclonal antibodies. Each approach has shown great promise in animal models and some successes in early clinical trials, but there remain significant barriers to highly effective therapy.
Albelda, Steven M, Thorne, Steve H
openaire   +2 more sources

Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a “Trojan Horse” in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas

Viruses, 2020
Several oncolytic viruses (OVs) including various human and canine adenoviruses, canine distemper virus, herpes-simplex virus, reovirus, and members of the poxvirus family, such as vaccinia virus and myxoma virus, have been successfully tested for canine
Ivan Petrov, Ivaylo Gentschev, Anna Vyalkova, Mohamed I. Elashry, Michele C. Klymiuk, Stefan Arnhold, Aladar A. Szalay   +6 more
doaj   +1 more source

Oncolytic Vaccinia Virus Therapy of Salivary Gland Carcinoma [PDF]

JAMA Otolaryngology–Head & Neck Surgery, 2013
To examine the therapeutic effects of an attenuated, replication-competent vaccinia virus (GLV-1h68) against a panel of 5 human salivary gland carcinoma cell lines.The susceptibility of 5 salivary gland carcinoma cell lines to infection and oncolysis by GLV-1h68 was assessed in vitro and in vivo.All 5 cell lines were susceptible to viral infection ...
Natalya, Chernichenko, Gary, Linkov, Pingdong, Li, Richard L, Bakst, Chun-Hao, Chen, Shuangba, He, Yong A, Yu, Nanhai G, Chen, Aladar A, Szalay, Yuman, Fong, Richard J, Wong   +10 more
openaire   +2 more sources